[Skip to Content]
[Skip to Content Landing]
Citations 0
Books, Journals, New Media
October 22/29, 2003

Cancer Drug

Author Affiliations
 

Books, Journals, New Media Section Editor: Harriet S. Meyer, MD, Contributing Editor, JAMA; David H. Morse, MS, University of Southern California, Norris Medical Library, Journal Review Editor.

JAMA. 2003;290(16):2194-2195. doi:10.1001/jama.290.16.2194

Its title and subtitle accurately convey this book's message. This is essentially a puff piece for Novartis, the Swiss pharmaceutical giant that made such a splash with its introduction of Gleevec, the breakthrough drug for chronic myelogenous leukemia (CML). Daniel Vasella, MD, chairman and CEO of the company, with the help of professional writer Robert Slater, gives us his version of how it all happened. And to hear him tell the story, the new drug was primarily the product of wise corporate management (his) and the contributions of a host of company scientists and technicians, whose work he encouraged.

First Page Preview View Large
First page PDF preview
First page PDF preview
×